Cumberland Pharmaceuticals Inc.
CPIX
$3.40
$0.144.29%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.84M | 11.71M | 9.11M | 9.09M | 9.85M |
| Total Other Revenue | -- | -- | 1.33M | -- | -- |
| Total Revenue | 10.84M | 11.71M | 10.44M | 9.09M | 9.85M |
| Cost of Revenue | 2.01M | 1.43M | 1.98M | 1.32M | 1.71M |
| Gross Profit | 8.83M | 10.29M | 8.46M | 7.76M | 8.14M |
| SG&A Expenses | 7.10M | 6.70M | 7.55M | 7.07M | 7.01M |
| Depreciation & Amortization | 1.01M | 1.01M | 1.46M | 1.08M | 1.10M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.58M | 10.42M | 12.28M | 10.78M | 10.88M |
| Operating Income | -747.50K | 1.29M | -1.84M | -1.69M | -1.03M |
| Income Before Tax | -729.50K | 1.25M | -1.96M | -1.53M | -1.09M |
| Income Tax Expenses | 5.70K | 5.70K | -57.00K | 11.40K | 11.40K |
| Earnings from Continuing Operations | -735.20K | 1.25M | -1.90M | -1.54M | -1.10M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -5.50K | 8.90K | -2.20K | -7.10K | 17.00K |
| Net Income | -740.70K | 1.26M | -1.90M | -1.54M | -1.09M |
| EBIT | -747.50K | 1.29M | -1.84M | -1.69M | -1.03M |
| EBITDA | 286.40K | 2.32M | -345.60K | -578.40K | 112.80K |
| EPS Basic | -0.05 | 0.08 | -0.14 | -0.11 | -0.08 |
| Normalized Basic EPS | -0.03 | 0.05 | -0.09 | -0.08 | -0.05 |
| EPS Diluted | -0.05 | 0.08 | -0.14 | -0.11 | -0.08 |
| Normalized Diluted EPS | -0.03 | 0.05 | -0.09 | -0.08 | -0.05 |
| Average Basic Shares Outstanding | 14.96M | 14.94M | 13.97M | 14.05M | 14.12M |
| Average Diluted Shares Outstanding | 14.96M | 15.26M | 13.97M | 14.05M | 14.12M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |